Nuvonis is a biotech company providing innovative cell banks for vaccine and vector production that will dramatically speed up your development. Nuvonis' experienced team provides technical support for virus production processes and vaccine strain improvement.

Nuvonis Avian Cell Banks (R&D and GMP)

Avian cells are suitable for the production of a variety of viruses, such as Vaccinia, Orthomyxoviridae, HSV Type I, Pseudorabies, Reovirus, Parainfluenza, Newcastle Disease Virus, MVA etc. Importantly, avian cell lines can replace Chicken Embryo Fibroblasts (CEF) or cultivation of viruses in embryonated hen’s eggs. Nuvonis has developed a novel continuous avian cell line (CCX) from primary quail (Coturnix japonica). Nuvonis avian cell banks are available both for adherent growth and growth in suspension.

Nuvonis Vero Cell Banks (R&D and GMP)

Vero cells are widely used for manufacturing a variety of viruses and vectors. Nuvonis provides “ready to use” GMP Master and GMP Working Cell Banks. Vero cell banks are produced under serum and animal-free media conditions. Vero cell banks are immediately available for GMP manufacturing and are fully characterized including tumorigenicity testing at the end of production level (EPCB).

Process Development Services

The Nuvonis team is highly experienced in developing and optimizing up- and downstream vaccine production processes and all aspects of vaccine development. Amongst other optimization techniques, we are offering a proprietary and efficient virus purification process for the generation of high-purity vaccine bulk drug substance, meeting regulatory requirements in terms of host cell DNA and host cell protein impurities.

Advantages

Why Nuvonis?

Rely on Cell Banks that are ready to use

Shorten the clinical evaluation timelines of your vaccine candidate and reduce time to market by 1-2 years. Save time and money, and rely on our experience!

Rely on fully characterized GMP compliant Cell Banks

Minimize your development risks by using a state-of-the-art cell bank that is fully tested according to international guidelines (US FDA cGMP – 21 Code of Federal Regulations, European Pharmacopoeia and ICH guidelines)

Latest blog articles

Abbildung des Newcastle Disease Virus

Nuvonis´ New Process for the Production and Purification of Newcastle Disease Virus as Alternative to Egg-based Production

Nuvonis has developed a new high-yield platform process for the production and purification of Newcastle disease virus (NDV). The process is based on a novel avian cell line CCX.E10, an alternative to traditional egg-based production and monolith chromatography for purification. This allows for robust manufacturing and enables new NDV product development. What is Newcastle Disease?

Read More »

Our partners

Nach oben scrollen

Select a language